Galectin Therapeutics Inc.
Company Snapshot: Galectin Therapeutics Inc.
Galectin Therapeutics (Nasdaq:GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company's unique understanding of galectin proteins, key mediators of biologic function. We are leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer.
- Jan 24 2023 Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
- Jan 5 2023 Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis
- Nov 29 2022 Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
- Nov 28 2022 Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit